$50m for London CHARM Therapeutics for deep minded folding expertise
CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology.
Biotalys first proteinbased biocontrol shows up in vineyards
Based on data from the latest trials in grapes across vineyards in diverse climates throughout California and New York, Biotalys’ biocontrol product Evoca provided superior preventative control of Botrytis bunch rot in grapevines compared to chemical standard. Approval is estimated within this year.
Andera Partners co-leads $118m Series B of Mineralys thx (USA)
Andera Partners, Paris based European private equity player, announced on Wednesday that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118m Series B financing for Mineralys Therapeutics, Inc., Philadelphia (USA), a private, clinical-stage biopharmaceutical company developing novel therapy for the treatment of hypertension.
From waste to sugar – demonstration plant opens in Wales
The South Wales-based demonstration plant "VAMOS" that generates industrial biotechnology sugars and other recycled material streams from the paper and card in mixed household waste has come online these days. The products will be used in the production of several high-performance bio-based materials.
International Vaccine Institute IVI will locate its European office in Stockholm
The International Vaccine Institute, IVI, which is associated with the WHO and UN, will locate its European office in Stockholm. To date, the institute is only located in the host country of South Korea.
Abliva decides on a SEK200m financing to fund Phase 2/3 study
The financing (around 19m) shall fully fund the commencement of a potentially pivotal/registrational Phase 2/3 study for KL1333 and its progression to the outcome of a key interim analysis.
Transine Therapeutics Ltd closes £13.7m seed financing
Transine Therapeutics Ltd has added £4.6m from lead investor Epidarex Capital and the Dementia Discovery Fund (DDF) to its £9.1m seed funding led by Takeda Ventures and DDF.
Orphan drug developer Minoryx raises 51m
Minoryx Therapeutics SL has closed a 51m financing, including Series C equity financing and complementary bank debt to commercialise X-ALD drug leriglitazone.
G7 heads call for decarbonisation of industry
G7 Climate, Energy and Environment Ministers have announced a wide range of actions to tackle the triple global crisis of climate change, biodiversity loss and pollution".
Ellipses Pharma licences SRB22 from SunRock Biopharma
Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein set to eliminate solid tumours.